Irene Boeddinghaus

Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial

Ian E. Smith, Mitch Dowsett, S. Ebbs et al. · Journal of Clinical Oncology · 2005 · 772 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Short-Term Changes in Ki-67 during Neoadjuvant Treatment of Primary Breast Cancer with Anastrozole or Tamoxifen Alone or Combined Correlate with Recurrence-Free Survival

Mitch Dowsett, Ian E. Smith, Steve R. Ebbs et al. · Clinical Cancer Research · 2005 · 350 citations · Full text

Medicine, Oncology, Pharmacology +13

Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT Trialists

Mitch Dowsett, Steve R. Ebbs, J. Michael Dixon et al. · Journal of Clinical Oncology · 2005 · 290 citations · Full text

Medicine, Endocrinology, Oncology +16

HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.

Mitch Dowsett, Catherine Harper‐Wynne, Irene Boeddinghaus et al. · PubMed · 2001 · 173 citations

Medicine, Endocrinology, Oncology +14

Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer

Mitch Dowsett, Ian E. Smith, Steve R. Ebbs et al. · Clinical Cancer Research · 2006 · 146 citations

Medicine, Endocrinology, Oncology +17